Company Filing History:
Years Active: 2010
Title: Innovations by Matthew B Elliott
Introduction
Matthew B Elliott is an accomplished inventor based in Branford, CT (US). He has made significant contributions to the field of virology, particularly in the development of recombinant respiratory syncytial virus (RSV) strains. His work aims to enhance the safety and efficacy of vaccines against RSV, a virus that poses serious health risks, especially to infants and the elderly.
Latest Patents
Matthew B Elliott holds a patent for "Recombinant RSV strains with altered G protein." This patent discloses the construction of recombinant RSV strains that have been modified to delete the region of the G protein most likely to induce unwanted type 2 T cell responses in susceptible recipients. Using reverse genetics, he engineered RSV strains with deletions of amino acids 151-221 and 178-219. Both strains were shown to replicate in the respiratory tract of BALB/c mice and elicited serum neutralization and anti-F protein IgG titers comparable to cp-RSV. Notably, these strains contributed to a 3.9 log reduction in RSV A2 four days after challenge. Importantly, pulmonary eosinophilia was significantly diminished in BALB/c mice that were primed with native G protein and subsequently challenged with either recombinant RSV strain. These findings are crucial for the development of immunogenic compositions against RSV.
Career Highlights
Matthew B Elliott is currently associated with Wyeth Holdings Corporation, where he continues to advance his research in virology and vaccine development. His innovative approaches have positioned him as a key figure in the fight against respiratory viruses.
Collaborations
Matthew has collaborated with Gerald E Hancock, contributing to the advancement of their shared research goals. Their partnership has fostered a productive environment for innovation in the field of virology.
Conclusion
Matthew B Elliott's work in developing recombinant RSV strains represents a significant advancement in vaccine research. His contributions are vital for improving public health outcomes related to respiratory syncytial virus.